Key result
This review summarizes the current literature on assessing cardiovascular risk of breast cancer therapies and discusses pharmacological and lifestyle strategies to prevent cardiovascular toxicity.
Why the study?
Novel cancer therapies have improved clinical outcomes in breast cancer, prompting the need to assess cardiovascular risk and evaluate strategies to prevent cardiovascular toxicity.
This review summarizes current literature on assessing cardiovascular risk and strategies to prevent cardiovascular toxicity in breast cancer patients.
Answers are grounded in this paper and cite their sources.
Preventive strategies may reduce cardiotoxicity in breast cancer therapy; leaves open confirmation in prospective trials.
Cardio-oncology is an emerging field tasked with identifying and treating cancer therapy related cardiac dysfunction (e.g., cytotoxic agents, immunotherapies, radiation, and hormone therapies) and optimizing the cardiovascular health of cancer patients exposed to these agents. Novel cancer therapies have led to significant improvements in clinical outcomes for breast cancer patients. In this article, we review the current literature on assessing cardiovascular risk of breast cancer therapies and discuss strategies (including pharmacological and lifestyle interventions) to prevent cardiovascular toxicity.
No takes yet. Share an insight, caveat, or question.
Kikuchi et al. (2020) conducted a review in Breast cancer. Pharmacological and lifestyle interventions was evaluated. This review summarizes the current literature on assessing cardiovascular risk of breast cancer therapies and discusses pharmacological and lifestyle strategies to prevent cardiovascular toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: